Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Could local surgery improve survival in de novo stage IV breast cancer?

Authors: Zhenchong Xiong, Guangzheng Deng, Jin Wang, Xing Li, Xinhua Xie, Zeyu Shuang, Xi Wang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Resection of the primary tumor is recommended for symptom relief in de novo stage IV breast cancer. We explored whether local surgery could provide a survival benefit in these patients and attempted to characterize the population that could benefit from surgery.

Methods

Metastatic Breast cancer patients (N = 313) with intact primary tumor between January 2006 and April 2013 were separated into two groups according to whether or not they had undergone surgery. The difference in characteristics between the two groups was analyzed using chi-square test, Fisher’s exact test and Mann-Whitney test. Univariable and multivariable Cox regression and stratified survival analysis were used to assess the effect of surgery on survival.

Results

Of the 313 patients, 188 (60.1%) underwent local surgery. Patients with local surgery had a 47% reduction in mortality risk vs. those with no surgery (median survival 78 months vs. 37 months; HR = 0.53; 95% CI, 0.36–0.78) after adjustment for clinical and tumor characteristics. Stratified survival analysis showed that patients with bone metastasis alone (and primary tumor ≤5 cm), soft tissue metastasis, or ≤ 3 metastasis sites benefit from surgery.

Conclusion

Surgical resection of the primary tumor can improve survival in selected de novo stage IV breast cancer patients.
Literature
1.
2.
Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial surgery and survival in stage IV breast Cancer in the United States, 1988-2011. JAMA Surg. 2016;151:424–31.CrossRefPubMedPubMedCentral
3.
Eng LG, Dawood S, Sopik V, Haaland B, Tan PS, Bhoo-Pathy N, Warner E, Iqbal J, Narod SA, Dent R. Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat. 2016;160:145–52.CrossRefPubMed
4.
Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, Budrukkar A, Mittra I, Gupta S. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. The Lancet Oncology. 2015;16:1380–8.CrossRefPubMed
5.
Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014;120:1319–28.CrossRefPubMed
6.
Shien T, Kinoshita T, Shimizu C, Hojo T, Taira N, Doihara H, Akashi-Tanaka S. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep. 2009;21:827–32.PubMed
7.
Hazard HW, Gorla SR, Scholtens D, Kiel K, Gradishar WJ, Khan SA. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer. 2008;113:2011–9.CrossRefPubMed
8.
Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer. Eur J Cancer. 2011;47(Suppl 3):S6–22.CrossRefPubMed
9.
Tan Y, Li X, Chen H, Hu Y, Jiang M, Fu J, Yuan Y, Ding K. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study. Oncotarget. 2016;7:70991–1000.PubMedPubMedCentral
10.
Rashaan ZM, Bastiaannet E, Portielje JE, van de Water W, van der Velde S, Ernst MF, van de Velde CJ, Liefers GJ. Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery. Eur J Surg Oncol. 2012;38:52–6.CrossRefPubMed
11.
Pathy NB, Verkooijen HM, Taib NA, Hartman M, Yip CH. Impact of breast surgery on survival in women presenting with metastatic breast cancer. Br J Surg. 2011;98:1566–72.CrossRefPubMed
12.
Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of Surgery with Improved Survival in stage IV breast Cancer patients. Ann Surg. 2008;247:732–8.CrossRefPubMed
13.
Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C. Complete excision of primary breast tumor improves survival of patients with metastatic breast Cancer at diagnosis. J Clin Oncol. 2006;24:2743–9.CrossRefPubMed
14.
Patrick J, Khan SA. Surgical management of de novo stage IV breast cancer. J Natl Compr Cancer Netw. 2015;13:487–93. quiz 493CrossRef
15.
Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast Cancer impacts on survival. Ann Surg Oncol. 2013;20:2828–34.CrossRefPubMed
16.
Neuman HB, Morrogh M, Gonen M, Van Zee KJ, Morrow M, King TA. Stage IV breast cancer in the era of targeted therapy. Cancer. 2010;116:1226–33.CrossRefPubMed
17.
Soran A, Ozbas S, Kelsey SF, Gulluoglu BM. Randomized trial comparing locoregional resection of primary tumor with no surgery in stage IV breast cancer at the presentation (protocol MF07-01): a study of Turkish Federation of the National Societies for breast diseases. Breast J. 2009;15:399–403.CrossRefPubMed
18.
Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol. 2008;15:3384–95.CrossRefPubMed
19.
Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical testing of estrogen and progesterone receptors in breast Cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedPubMedCentral
20.
Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005;23:4287–97.CrossRefPubMed
21.
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRefPubMedPubMedCentral
22.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M. strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast Cancer 2011. Ann Oncol. 2011;22:1736–47.CrossRefPubMedPubMedCentral
23.
Xiong Z, Deng G, Huang X, Li X, Xie X, Wang J, Shuang Z, Wang X. Score for the survival probability in metastasis breast Cancer: a nomogram-based risk assessment model. Cancer Res Treat. 2018;
24.
25.
Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, Andre F. Precision medicine for metastatic breast cancer--limitations and solutions. Nat Rev Clin Oncol. 2015;12:693–704.CrossRefPubMed
26.
Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 1996;32A:2534–9.CrossRefPubMed
27.
Fisher ER, Fisher B. Experimental studies of factors influencing the development of hepatic metastases. Xiii. Effect of hepatic trauma in Parabiotic pairs. Cancer Res. 1963;23:896–900.PubMed
28.
Al-Sahaf O, Wang JH, Browne TJ, Cotter TG, Redmond HP. Surgical injury enhances the expression of genes that mediate breast cancer metastasis to the lung. Ann Surg. 2010;252:1037–43.CrossRefPubMed
29.
Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.CrossRefPubMed
30.
Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139:961–6. discussion 966-967CrossRefPubMed
31.
Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, Millis JM, Posner MC. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg. 2000;135:530–4. discussion 534-535CrossRefPubMed
32.
Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, Bear HD, Takabe K. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery. 2013;153:771–8.CrossRefPubMed
33.
Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64:2205–11.CrossRefPubMed
34.
Shien T, Nakamura K, Shibata T, Kinoshita T, Aogi K, Fujisawa T, Masuda N, Inoue K, Fukuda H, Iwata H. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan clinical oncology group study JCOG1017. Jpn J Clin Oncol. 2012;42:970–3.CrossRefPubMed
35.
Ruiterkamp J, Ernst MF, Van de poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC: surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 2009, 35:1146–1151.
36.
Xiong Z, Deng G, Huang X, Li X, Xie X, Wang J, Shuang Z, Wang X. Bone metastasis pattern in initial metastatic breast cancer: a population-based study. Cancer Manag Res. 2018;10:287–95.CrossRefPubMedPubMedCentral
37.
Briasoulis E, Karavasilis V, Kostadima L, Ignatiadis M, Fountzilas G, Pavlidis N. Metastatic breast carcinoma confined to bone: portrait of a clinical entity. Cancer. 2004;101:1524–8.CrossRefPubMed
Metadata
Title
Could local surgery improve survival in de novo stage IV breast cancer?
Authors
Zhenchong Xiong
Guangzheng Deng
Jin Wang
Xing Li
Xinhua Xie
Zeyu Shuang
Xi Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4767-x

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors

Technical advance

An advanced glioma cell invasion assay based on organotypic brain slice cultures

Research article

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis

Study protocol

Study protocol of the RaPS study: novel risk adapted prevention strategies for people with a family history of colorectal cancer

Research article

Liver cancer mortality trends in South Africa: 1999–2015

Research article

Safety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian tumours
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits